← back to search

Yongchang Zhang

Central South University · CN
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, and Lung Cancer Diagnosis and Treatment.
h-index
27
citations
3,000
works
235
NIH funding
primary concept
Medicine
email

Recent publications

Spatial immune scoring system predicts hepatocellular carcinoma recurrence
Nature 2025cited by 67position: middledoi
Taletrectinib in <i>ROS1</i> + Non–Small Cell Lung Cancer: TRUST
Journal of Clinical Oncology 2025cited by 41position: middledoi
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, <i>EGFR</i> -Mutated Advanced NSCLC
New England Journal of Medicine 2025cited by 28position: middledoi
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration
Cancer Biology and Medicine 2025cited by 4position: middledoi
Expert Consensus on the Diagnosis and Treatment of Malignant Mesothelioma of the Tunica Vaginalis Testis
iMetaMed 2025cited by 3position: middledoi
RC108 in combination with furmonertinib in patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) with MET overexpression: Results from a phase Ib/II trial.
Journal of Clinical Oncology 2025cited by 2position: middledoi
First in human phase I study of TQB2103, a Claudin18.2 (CLDN18.2) targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Journal of Clinical Oncology 2025cited by 2position: middledoi
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation
The Journal of Experimental Medicine 2024cited by 21position: middledoi
Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid Tumors
Global Medical Genetics 2024cited by 14position: middledoi
Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations
The Innovation 2024cited by 12position: middledoi
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody‐drug conjugates–induced interstitial lung disease/pneumonitis: An expert consensus in China
Cancer 2024cited by 10position: middledoi
Crizotinib resistance reversal in ALK-positive lung cancer through zeolitic imidazolate framework-based mitochondrial damage
Acta Biomaterialia 2024cited by 8position: middledoi
Expert Consensus on the Diagnosis and Treatment of FGFR Gene-Altered Solid Tumors
Global Medical Genetics 2024cited by 7position: middledoi
Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma
Journal for ImmunoTherapy of Cancer 2023cited by 35position: middledoi
Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors
Thoracic Cancer 2023cited by 27position: middledoi
Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma
Thoracic Cancer 2023cited by 19position: middledoi
Expert consensus on treatment for stage III non‐small cell lung cancer
Medicine Advances 2023cited by 18position: middledoi
Expert consensus on the diagnosis and treatment of <scp>RET</scp> gene fusion <scp>non‐small</scp> cell lung cancer in <scp>China</scp>
Thoracic Cancer 2023cited by 12position: middledoi
Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study
European Journal of Cancer 2022cited by 21position: middledoi
Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor
Thoracic Cancer 2022cited by 19position: middledoi
Chinese expert consensus on the diagnosis and treatment of <scp>HER2</scp>‐altered non–small cell lung cancer
Thoracic Cancer 2022cited by 17position: middledoi
Expert consensus on the diagnosis and treatment of <scp><i>NTRK</i></scp> gene fusion solid tumors in China
Thoracic Cancer 2022cited by 17position: middledoi
Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients
Cancer Medicine 2022cited by 12position: middledoi
ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis
Cancer Cell 2020cited by 258position: middledoi
EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases
European Journal of Cancer 2019cited by 55position: middledoi
A new glimpse of FadR-DNA crosstalk revealed by deep dissection of the E. coli FadR regulatory protein
Protein & Cell 2014cited by 9position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

C. Xu · Sun Yat-sen University Cancer Center2 papers (2022–2022)Gen Lin · Fujian Provincial Cancer Hospital2 papers (2022–2022)Jing Cai · Union Hospital2 papers (2022–2022)Qian Wang · Nanjing University of Chinese Medicine2 papers (2022–2022)Caicun Zhou · Tongji University2 papers (2019–2025)Yue Hao · Xinjiang Medical University2 papers (2022–2022)Zhengbo Song · Institute of Hematology & Blood Diseases Hospital2 papers (2022–2022)Wenxian Wang · Fudan University2 papers (2022–2022)Wei Li · Shanghai Cancer Institute1 papers (2025–2025)Xianyu Zhang · Hebei Medical University1 papers (2025–2025)Tianxiang Chen · Nanchang University1 papers (2024–2024) · 1 papers (2025–2025)Mengzhao Wang · Kunming University of Science and Technology1 papers (2023–2023) · 1 papers (2024–2024)Xiaoxia Chen · Fudan University1 papers (2019–2019)Xicheng Wang · Qilu Hospital of Shandong University1 papers (2025–2025)Bo Yang · Union Hospital1 papers (2025–2025)Yu Ding · Fudan University1 papers (2025–2025)Joe Yeong · National University of Singapore1 papers (2025–2025)Xiaoqun Ye · Nanchang University1 papers (2024–2024)